Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palatin

0.0941
0.0000
Volume:- -
Turnover:- -
Market Cap:2.65M
PE:-0.06
High:0.0941
Open:0.0941
Low:0.0941
Close:0.0941
Loading ...

Palatin Technologies Reports Reduced Net Loss of $4.8 Million and EPS of $(0.18) for Q1 2025 Amid Absence of Product Sales

Reuters
·
14 May

Press Release: Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Dow Jones
·
14 May

Director Robert K. deVeer Jr. Reports Acquisition of Common Shares in Palatin Technologies Inc

Reuters
·
13 May

Palatin Technologies to Transition to OTC Pink Market Amid NYSE American Delisting, Plans to Appeal Decision

Reuters
·
08 May

Palatin Technologies Announces Transition to Otc Pink Following Nyse American Delisting Notice

THOMSON REUTERS
·
08 May

BRIEF-NYSE American To Commence Delisting Proceedings Against Palatin Technologies

Reuters
·
08 May

Nyse American to Commence Delisting Proceedings Against Palatin Technologies

THOMSON REUTERS
·
08 May

Amex Halt News Pending Lst 0.094100

THOMSON REUTERS
·
08 May

Palatin Technologies Stock Trading Halted Pending Material Announcement

MT Newswires Live
·
08 May

Palatin trading halted, news pending

TIPRANKS
·
08 May

BRIEF-Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering

Reuters
·
07 May

BRIEF-Palatin Expects $11.5 Million Financing To Cure NYSE American Delisting Notice

Reuters
·
07 May

Palatin Expects $11.5 Million Financing to Cure Nyse American Delisting Notice

THOMSON REUTERS
·
07 May

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

THOMSON REUTERS
·
07 May

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

PR Newswire
·
05 May

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses From Phase 3 Pl9643 Melody-1 Clinical Trial in Dry Eye Disease

THOMSON REUTERS
·
29 Apr

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

PR Newswire
·
29 Apr

Palatin Technologies Inc - Phase 2 Trial Showed Significant Weight Loss With Bremelanotide and Tirzepatide

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Ind Filings Expected by End of Q4 2025

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Low-Dose Bremelanotide Prevented Appetite Rebound After Tirzepatide Cessation

THOMSON REUTERS
·
17 Apr